Affinage

ANXA7

Annexin A7 · UniProt P20073

Length
488 aa
Mass
52.7 kDa
Annotated
2026-04-28
31 papers in source corpus 22 papers cited in narrative 22 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA7 is a calcium- and phospholipid-binding protein with intrinsic GTPase activity that functions as a tumor suppressor, a regulator of intracellular calcium signaling, and an adaptor linking ribonucleoprotein cargo to the dynein motor for retrograde axonal transport. Its GTPase activity, dependent on endonexin-fold calcium-binding motifs, drives membrane fusion, IP3 receptor expression, and downstream signaling through AMPK/mTORC1/STAT3 and PI3K/AKT/mTOR pathways; loss of ANXA7 in mice causes profound reduction of IP3 receptor function, impaired insulin secretion, genomic instability, and cancer susceptibility (PMID:10570150, PMID:14608035, PMID:37240163). ANXA7 suppresses oncogenic low-molecular-weight cyclin E and Cyclin B1 expression, activates FOXO3A-dependent apoptosis, and its tumor suppressor activity is abrogated by dominant-negative mutations that impair calcium/phospholipid binding (PMID:11287641, PMID:24864229, PMID:30369774, PMID:39308302). Beyond cancer, ANXA7 translocates to damaged mitochondria to promote Parkin-dependent mitophagy via BASP1 interaction, stabilizes PPARγ to drive lipid droplet formation and NRF2/GPX4-mediated anti-ferroptotic protection in neurons, interacts with LAMP5 to maintain lysosomal function and autophagy, and is itself targeted for ubiquitin-dependent degradation by RNF168, linking its loss to NLRP3 inflammasome activation and Crohn's disease pathology (PMID:31975592, PMID:37620352, PMID:39996504, PMID:41518435).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1999 High

    Establishing ANXA7 as a Ca²⁺-activated GTPase essential for IP3 receptor expression and insulin secretion resolved how this annexin family member couples calcium signaling to secretory function in vivo.

    Evidence Anx7 knockout mouse with electrophysiology, Ca²⁺ imaging, and insulin secretion assays

    PMID:10570150

    Open questions at the time
    • GTPase catalytic mechanism not structurally resolved
    • whether GTPase activity is required for IP3R regulation was not tested by point mutation
  2. 2001 High

    Demonstrating that wild-type ANXA7 reintroduction suppresses prostate cancer cell proliferation and colony formation established ANXA7 as a bona fide tumor suppressor, connecting its biochemical activity to growth control.

    Evidence wt-ANXA7 transfection into LNCaP and DU145 cells with proliferation and colony formation assays, LOH analysis in human tissue

    PMID:11287641

    Open questions at the time
    • molecular target through which ANXA7 arrests proliferation was unidentified
    • in vivo tumor suppression not directly tested
  3. 2003 High

    Showing that Anx7 haploinsufficiency causes genomic instability, reduced expression of tumor suppressors and DNA repair genes, and a cancer-prone phenotype in mice placed ANXA7 upstream of a broad genomic maintenance network.

    Evidence Anx7+/- knockout mouse with genome array analysis and spectral karyotyping

    PMID:14608035

    Open questions at the time
    • direct mechanism linking ANXA7 to DNA repair gene regulation unknown
    • whether GTPase activity mediates genomic stability not tested
  4. 2010 Medium

    Identifying a multi-hnRNP complex that binds the ANXA7 promoter and causes aberrant splicing in androgen-resistant prostate cancer revealed a transcriptional mechanism for ANXA7 silencing in cancer.

    Evidence Promoter deletion mapping, EMSA, MALDI-TOF MS, and hnRNP A2/B1 antibody interference in PC3 cells

    PMID:20190808

    Open questions at the time
    • whether hnRNP-mediated silencing occurs in primary tumors not shown
    • splice variants not functionally characterized
  5. 2012 Medium

    Discovery that BART–ANXA7 complex translocates to cell protrusions and inhibits PKCα activity linked ANXA7 to regulation of cell migration and invasiveness beyond its canonical tumor suppressor role.

    Evidence Co-IP, PKCα activity assay, BART/ANXA7 siRNA knockdown, and invasion assays in pancreatic cancer cells

    PMID:22532868

    Open questions at the time
    • structural basis of BART–ANXA7 interaction unknown
    • single Co-IP without reciprocal pulldown from endogenous lysates
  6. 2014 Medium

    Showing that ANXA7 preserves FOXO3A from hyperphosphorylation and enables its nuclear translocation for proapoptotic transcription defined a mechanistic pathway distinct from p53 by which ANXA7 triggers apoptosis.

    Evidence ANXA7 transfection into LNCaP cells, phospho-FOXO3A western blot, cell cycle and apoptosis assays

    PMID:24864229

    Open questions at the time
    • whether ANXA7 directly binds FOXO3A or acts through SGK1/Akt not resolved
    • single cell line
  7. 2017 Medium

    Demonstrating that ANXA7 GTPase activation feeds into AMPK/mTORC1/STAT3 signaling and that RKIP binding impairs this activation established a GTPase-centric signal transduction model for ANXA7's anti-metastatic activity.

    Evidence SEC small molecule activator, RKIP–ANXA7 Co-IP, pathway analysis, orthotopic prostate cancer metastasis model

    PMID:29247827

    Open questions at the time
    • direct GTPase kinetic parameters with RKIP not measured
    • SEC specificity for ANXA7 versus other annexins not addressed
  8. 2018 Medium

    Showing that wild-type but not dominant-negative ANXA7 (lacking phosphatidylserine binding) abolishes oncogenic LMW-cyclin E linked ANXA7's membrane fusion properties to cell cycle regulation.

    Evidence wt vs. nMMM-ANXA7 transfection, western blot for LMW-cyclin E and FGF8, cell cycle analysis in DU145 and breast cancer cells

    PMID:30369774

    Open questions at the time
    • mechanism connecting phospholipid binding to cyclin E regulation not identified
    • limited to overexpression system
  9. 2020 Medium

    Identifying ANXA7 translocation to impaired mitochondria and its interaction with BASP1 during Parkin-dependent mitophagy expanded ANXA7 function beyond secretion and cancer to organelle quality control.

    Evidence Quantitative mitochondrial DIA proteomics, CCCP-induced mitophagy, ANXA7 KD, Co-IP of ANXA7–BASP1

    PMID:31975592

    Open questions at the time
    • whether ANXA7 GTPase activity is required for mitophagy not tested
    • BASP1–ANXA7 interaction not validated by reciprocal approach
  10. 2023 Medium

    Mutagenesis of endonexin-fold GX(X)GT motifs proved that calcium/phospholipid binding is required for ANXA7's membrane fusion, IP3R regulation, and tumor suppressor functions, unifying its biochemical and cellular activities.

    Evidence Active-site mutagenesis of ANXA7 endonexin folds, in vitro membrane fusion assay, Ca²⁺/phospholipid binding, IP3R and PI3K/AKT/mTOR pathway analysis

    PMID:37240163

    Open questions at the time
    • no crystal structure of mutant ANXA7 to verify fold integrity
    • in vivo tumor suppression by mutant not tested
  11. 2023 Medium

    Demonstrating that ANXA7 interacts with LAMP5 via Asp411 to maintain lysosomal acidity and promote mTOR/TFEB-dependent autophagy after neuronal injury provided a neuroprotective mechanism for ANXA7 GTPase activity.

    Evidence OGD/R neuronal model, Co-IP of ANXA7–LAMP5, Asp411 mutagenesis, in vivo SCI mouse model with lentiviral ANXA7 OE

    PMID:37620352

    Open questions at the time
    • whether LAMP5 interaction is Ca²⁺-dependent not tested
    • single mutagenesis site without comprehensive domain mapping
  12. 2025 Medium

    Showing that ANXA7 GTPase activation stabilizes PPARγ, drives lipid droplet biogenesis, and engages NRF2/GPX4 anti-ferroptotic signaling linked ANXA7 to lipid metabolism and oxidative stress defense in neurons.

    Evidence Co-IP of ANXA7–PPARγ, PPARγ stability assay, lipid droplet imaging, NRF2/GPX4 pathway analysis, in vivo SCI model

    PMID:39996504

    Open questions at the time
    • direct vs. indirect stabilization of PPARγ not distinguished
    • whether this pathway operates outside neuronal injury context unknown
  13. 2025 Medium

    Identifying ANXA7 as an adaptor linking TIA1-containing RNP granules to cytoplasmic dynein for retrograde axonal transport revealed an entirely new cell-biological role for this annexin in neuronal homeostasis.

    Evidence (preprint) Live axonal transport imaging, ANXA7 KD/OE in neurons, Co-IP of ANXA7–TIA1–dynein complex, Ca²⁺ elevation experiments

    PMID:bio_10.1101_2025.01.16.633295

    Open questions at the time
    • preprint not yet peer-reviewed
    • whether Ca²⁺-dependent uncoupling involves GTPase activity not tested
    • structural basis of ANXA7–dynein interaction unknown
  14. 2026 Medium

    Demonstrating that RNF168 ubiquitinates and degrades ANXA7, suppressing autophagy and promoting NLRP3 inflammasome-driven pyroptosis, established a post-translational regulatory mechanism for ANXA7 levels with disease relevance in Crohn's disease.

    Evidence Co-IP and ubiquitination assays, ANXA7 KD/OE in NCM460 cells, RNF168flox/flox;Villin-Cre mice with TNBS colitis, organoid experiments

    PMID:41518435

    Open questions at the time
    • ubiquitination sites on ANXA7 not mapped
    • whether RNF168-ANXA7 axis operates in non-intestinal contexts unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis of ANXA7 GTPase activity, the identity of a physiological GEF or GAP, and how GTPase cycling is coordinated with calcium-dependent membrane binding remain unresolved.
  • no crystal or cryo-EM structure of ANXA7
  • no GEF/GAP identified
  • GTPase kinetic parameters under physiological conditions not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003924 GTPase activity 5 GO:0098772 molecular function regulator activity 3 GO:0008289 lipid binding 2 GO:0060090 molecular adaptor activity 1
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0005886 plasma membrane 2 GO:0005739 mitochondrion 1 GO:0005764 lysosome 1 GO:0005811 lipid droplet 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-5357801 Programmed Cell Death 5 R-HSA-1640170 Cell Cycle 4 R-HSA-1643685 Disease 3 R-HSA-9612973 Autophagy 3 R-HSA-382551 Transport of small molecules 2
Partners
BARTBASP1LAMP5PPARGRKIPTIA1XRN2ZBTB16

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 ANX7 encodes a Ca2+-activated GTPase that supports Ca2+/GTP-dependent secretion events and Ca2+ channel activities; knockout of anx7 in mice results in profound reduction of IP3 receptor expression and function in pancreatic islets, directly linking ANX7 to IP3-dependent Ca2+ signaling and insulin secretion. Anx7 knockout mouse model (anx7+/- and -/-), electrophysiology, electrooptical recordings of intracellular calcium, insulin secretion assays Proceedings of the National Academy of Sciences of the United States of America High 10570150
2001 Wild-type ANXA7 acts as a tumor suppressor gene in prostate cancer; transfection of wt-ANX7 into LNCaP and DU145 prostate tumor cell lines markedly reduces cell proliferation and colony formation. Transfection of wt-ANX7 into tumor cell lines, proliferation assays, colony formation assays, loss-of-heterozygosity analysis with microsatellite markers Proceedings of the National Academy of Sciences of the United States of America High 11287641
2003 Haploinsufficiency of Anx7 in mice leads to genomic instability, reduced expression of tumor suppressor genes, DNA repair genes, and apoptosis-related genes, and cancer-prone phenotype with chromosomal instability, placing ANXA7 upstream of a discrete tumor suppressor signaling pathway. Anx7+/- knockout mouse, genome array analysis, spectral karyotyping, tissue imprinting, laser-capture microdissection Proceedings of the National Academy of Sciences of the United States of America High 14608035
2002 In Anx7+/- knockout mice, adrenal chromaffin cells are unable to discriminate between fed and fasted states, with sustained expression of nutritionally sensitive genes (chromogranin A/B, DbetaH), implicating the ANX7/IP3R signaling axis in nutrient-regulated secretory gene expression in chromaffin cells. Anx7+/- knockout mouse, cDNA microarray, feeding/fasting challenge Annals of the New York Academy of Sciences Medium 12438089
2010 A multi-hnRNP complex (hnRNP A1, A2/B1, K) binds to the steroid nuclear hormone receptor element cluster in the ANXA7 promoter in androgen-resistant prostate cancer cells (PC3), causing aberrant ANXA7 transcription and splicing; hnRNP A2/B1 antibody interference validates this regulatory role. Deletion mapping/promoter reporter assays, gelshift/EMSA, MALDI-TOF mass spectrometry, hnRNP A2/B1 antibody interference, RT-PCR, western blot Oncogene Medium 20190808
2012 BART (binder of Arl two) binds directly to ANX7, and the BART-ANX7 complex translocates to cell protrusions in migrating cells where it reduces PKCα activity; knockdown of BART or ANX7 increases PKCα activity and enhances invasiveness of pancreatic cancer cells, which is abrogated by PKCα inhibitors. Co-IP, pulldown, PKCα activity assay, BART/ANX7 siRNA knockdown, invasion assays, confocal imaging of complex localization PloS one Medium 22532868
2012 In Anx7+/- mouse beta-cells, muscarinic agonist (carbachol) and ryanodine receptor agonists (caffeine, 4-chloro-m-cresol) elicit more potent depolarizing effects and augmented insulin secretion compared to controls, demonstrating that the Anx7+/- mutation alters IP3 receptor and ryanodine receptor signaling pathways regulating beta-cell membrane potential. Anx7+/- knockout mouse, electrophysiology, intracellular Ca2+ measurements, insulin secretion assays, pharmacological agonists Cellular physiology and biochemistry Medium 22613970
2014 Wild-type ANXA7 in LNCaP prostate cancer cells preserves total FOXO3A expression without hyperphosphorylation, enabling FOXO3A nuclear translocation and proapoptotic transcription, while inducing G1-arrest and programmed cell death; this is mechanistically distinct from p53 effects and linked to SGK1/FOXO3A/Akt pathway regulation. ANXA7 and p53 transfection into LNCaP cells, western blot for phospho/total FOXO3A, cell cycle analysis, apoptosis assays, Ingenuity Pathway Analysis BioMed research international Medium 24864229
2016 Inhibition of ANXA7 GTPase activity by small molecule ABO elevates HMBOX1 protein through translational upregulation; ANXA7 translocates to the nucleus upon GTPase inhibition and interacts with XRN2, reducing XRN2 phosphorylation and promoting TGFB2-OT1 lncRNA expression, which increases LARP1 and subsequently HMBOX1 translation. Small molecule ABO treatment, ANXA7-deficient HUVECs, western blot, ANXA7 nuclear fractionation, Co-IP of ANXA7-XRN2, lncRNA microarray, in vivo apoE-/- mouse model The international journal of biochemistry & cell biology Medium 27506770
2017 Activation of ANXA7 GTPase by small molecule SEC promotes AMPK phosphorylation, leading to decreased mTORC1 activity, suppressed STAT3 nuclear translocation, and downregulation of pro-metastatic genes (CCL2, APLN, IL6ST); RKIP interacts with ANXA7 and impairs SEC-induced ANXA7 GTPase activation and downstream signaling. SEC small molecule treatment, RKIP-ANXA7 Co-IP, AMPK/mTORC1/STAT3 pathway analysis, in vivo orthotopic prostate cancer metastasis assay Cancer letters Medium 29247827
2018 Wild-type ANXA7 abolishes expression of oncogenic low-molecular weight (LMW) cyclin E in hormone-resistant prostate (DU145) and breast cancer cells; dominant-negative nMMM-ANXA7 (lacking phosphatidylserine liposome aggregation properties) fails to abrogate LMW-cyclin E and simultaneously induces FGF8 in DU145, consistent with continuing cell cycle progression. wt-ANXA7 and dominant-negative ANXA7 transfection, western blot for LMW-cyclin E and FGF8, cell cycle analysis, apoptosis assays in multiple cancer cell lines Trends in cancer research Medium 30369774
2019 Inhibition of ANXA7 GTPase activity by ABO causes ANXA7 to translocate into the nucleus where it interacts with XRN2; reduced XRN2 phosphorylation promotes read-through transcription of MROH7-TTC4 lncRNA, which is processed by TIA1 into MROH7 and TTC4 that inhibit VEC apoptosis. ABO GTPase inhibitor, nuclear fractionation/localization of ANXA7, Co-IP of ANXA7-XRN2, lncRNA microarray, TIA1 pulldown, apoptosis assays in HUVECs The FEBS journal Medium 31408583
2019 ANXA7 knockdown inhibits JAK1/STAT3 pathway activation in trophoblast cells, reduces BCL2 protein levels, induces apoptosis, and inhibits proliferation; ANXA7 overexpression has the opposite effects, placing ANXA7 upstream of the JAK1/STAT3 anti-apoptotic pathway in trophoblasts. ANXA7 siRNA knockdown and overexpression in HTR-8/SVneo cells, western blot for BCL2/JAK1/STAT3, flow cytometry for apoptosis, CCK-8 proliferation assay American journal of reproductive immunology Medium 31446642
2020 ANXA7 translocates to impaired mitochondria upon CCCP treatment and interacts with BASP1 to play a pivotal role in Parkin-dependent mitophagy. Quantitative mitochondrial proteomics (DIA), CCCP-induced mitophagy assay, ANXA7 KD, Co-IP of ANXA7-BASP1, mitochondrial fractionation Journal of proteome research Medium 31975592
2020 ANXA7 promotes proliferation, cell cycle progression, and cell adhesion-mediated drug resistance in multiple myeloma cells by directly binding to and upregulating CDC5L. Co-IP of ANXA7-CDC5L, ANXA7 overexpression and knockdown in MM cell lines, CDC5L siRNA rescue experiments, proliferation/apoptosis/cell cycle assays Aging Medium 32526706
2023 A dominant-negative triple mutant of ANXA7 (DNTM/DN-ANXA7J, mutating GX(X)GT motifs in endonexin-fold repeats) suppresses membrane fusion with artificial membranes, alters calcium and phospholipid binding, reduces IP3 receptor expression, and modulates PI3K/AKT/mTOR signaling in prostate cancer cells, demonstrating that calcium/phospholipid binding by ANXA7 is required for its tumor suppressor function. Active-site mutagenesis of ANXA7 endonexin folds, in vitro membrane fusion assay, calcium/phospholipid binding assay, IP3 receptor western blot, PI3K/AKT/mTOR pathway analysis, apoptosis assays in prostate cancer cells International journal of molecular sciences Medium 37240163
2023 ANXA7 GTPase activation protects neurons after OGD/R by enhancing autophagy via the mTOR/TFEB pathway and inhibiting apoptosis; ANXA7 directly interacts with lysosomal membrane protein LAMP5 (with Asp411 mutation impairing this interaction), and ANXA7 stabilizes LAMP5 protein expression to maintain lysosomal acidic environment. OGD/R neuronal model, ANXA7 GTPase activation/inhibition, Co-IP of ANXA7-LAMP5, Asp411 mutagenesis, LAMP5 overexpression rescue, mTOR/TFEB pathway analysis, in vivo SCI mouse model with lentiviral ANXA7 overexpression, CatWalk assay Cell death discovery Medium 37620352
2024 ZBTB16 directly interacts with ANXA7 protein (validated by Co-IP), and ZBTB16 promotes ANXA7 expression which subsequently inhibits Cyclin B1 expression; this ZBTB16/ANXA7/Cyclin B1 axis mediates cell cycle arrest and apoptosis in breast cancer cells downstream of UHRF1 knockdown. Co-IP of ZBTB16-ANXA7, ANXA7 KD rescue experiments, Cyclin B1 western blot, cell cycle and apoptosis assays, methylation-specific PCR, ChIP for UHRF1/DNMT1 at ZBTB16 promoter Acta biochimica et biophysica Sinica Medium 39308302
2025 ANXA7 acts as a critical adaptor for retrograde axonal transport by physically linking TIA1-containing RNPs to cytoplasmic dynein; persistent axonal Ca2+ elevation or ANXA7 knockdown decouples TIA1 granules from dynein, impairing retrograde transport and causing pathological TIA1 aggregation and axonopathy; ANXA7 overexpression enhances RNP trafficking and counteracts TIA1 aggregation. Live imaging of axonal transport, ANXA7 KD and OE in neurons, Co-IP of ANXA7-TIA1-dynein complex, Ca2+ elevation experiments, in vitro and in vivo axonopathy models bioRxivpreprint Medium bio_10.1101_2025.01.16.633295
2025 ANXA7 GTPase activation promotes lipid droplet formation by interacting with PPARγ to enhance its stability and nuclear translocation, driving Perilipin 5 expression and mitochondria-lipid droplet interaction; this inhibits lipid peroxidation through NRF2/GPX4 and reduces oxidative stress and neuron damage after spinal cord injury. Co-IP of ANXA7-PPARγ, ANXA7 GTPase activation, PPARγ stability assay, lipid droplet imaging, NRF2/GPX4 western blot, in vivo SCI mouse model Advanced science Medium 39996504
2026 RNF168 E3 ubiquitin ligase promotes ubiquitination and degradation of ANXA7; reduced ANXA7 levels suppress autophagy and enhance NLRP3 inflammasome-mediated pyroptosis in intestinal epithelial cells, driving Crohn's disease progression. Co-IP and ubiquitination assays (RNF168-ANXA7), ANXA7 KD and OE in NCM460 cells, autophagy and NLRP3 pyroptosis assays, IL-10 KO and RNF168flox/flox;Villin-Cre mice with TNBS colitis, organoid experiments Apoptosis Medium 41518435
2014 LEPR (Leptin Receptor) physically interacts with ANXA7 (validated by Co-IP), and mechanistically regulates ERK1/2 and JAK2/STAT3 signaling through ANXA7 in hepatocellular carcinoma lymphatic metastatic cells. Co-immunoprecipitation of LEPR-ANXA7, western blot for ERK1/2 and JAK2/STAT3, LEPR knockdown/overexpression functional assays Cancer cell international Low 33397392

Source papers

Stage 0 corpus · 31 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 ANX7, a candidate tumor suppressor gene for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 108 11287641
1999 Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse. Proceedings of the National Academy of Sciences of the United States of America 108 10570150
2003 Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proceedings of the National Academy of Sciences of the United States of America 69 14608035
2007 ANXA7 expression represents hormone-relevant tumor suppression in different cancers. International journal of cancer 44 17708571
2001 ANX7 as a bio-marker in prostate and breast cancer progression. Disease markers 29 11673658
2010 Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells. Oncogene 27 20190808
2011 ANXA7, PPP3CB, DNAJC9, and ZMYND17 genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function. Biological psychiatry 25 21531385
2017 SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. Cancer letters 24 29247827
2019 ANXA7 regulates trophoblast proliferation and apoptosis in preeclampsia. American journal of reproductive immunology (New York, N.Y. : 1989) 21 31446642
2008 The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer. Journal of surgical oncology 20 18449914
2012 The Anx7(+/-) knockout mutation alters electrical and secretory responses to Ca(2+)-mobilizing agents in pancreatic β-cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 19 22613970
2021 Leptin Receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer cell international 18 33397392
2021 circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis. Cancer cell international 18 33536022
2016 Inhibition of ANXA7 GTPase activity by a small molecule promotes HMBOX1 translation of vascular endothelial cells in vitro and in vivo. The international journal of biochemistry & cell biology 18 27506770
2013 Down-regulation of ANXA7 decreases metastatic potential of human hepatocellular carcinoma cells in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 17 23582794
2023 Targeting ANXA7/LAMP5-mTOR axis attenuates spinal cord injury by inhibiting neuronal apoptosis via enhancing autophagy in mice. Cell death discovery 16 37620352
2020 ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L. Aging 16 32526706
2017 ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities. Methods in molecular biology (Clifton, N.J.) 15 27807828
2012 BART inhibits pancreatic cancer cell invasion by PKCα inactivation through binding to ANX7. PloS one 15 22532868
2020 Quantitative Mitochondrial Proteomics Reveals ANXA7 as a Crucial Factor in Mitophagy. Journal of proteome research 12 31975592
2018 High ANXA7 Potentiates Eucalyptol Toxicity in Hormone-refractory Prostate Cancer. Anticancer research 11 29970503
2019 MROH7-TTC4 read-through lncRNA suppresses vascular endothelial cell apoptosis and is upregulated by inhibition of ANXA7 GTPase activity. The FEBS journal 10 31408583
2014 Diverse effects of ANXA7 and p53 on LNCaP prostate cancer cells are associated with regulation of SGK1 transcription and phosphorylation of the SGK1 target FOXO3A. BioMed research international 9 24864229
2002 Influence of the Anx7 (+/-) knockout mutation and fasting stress on the genomics of the mouse adrenal gland. Annals of the New York Academy of Sciences 8 12438089
2025 Lipid Droplets Metabolism Mediated by ANXA7-PPARγ Signaling Axis Regulates Spinal Cord Injury Repair in Mice. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 7 39996504
2018 Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin. Trends in cancer research 7 30369774
2023 A Dominant-Negative Mutant of ANXA7 Impairs Calcium Signaling and Enhances the Proliferation of Prostate Cancer Cells by Downregulating the IP3 Receptor and the PI3K/mTOR Pathway. International journal of molecular sciences 6 37240163
1999 HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication. Proceedings of the National Academy of Sciences of the United States of America 4 10077575
2024 UHRF1 knockdown induces cell cycle arrest and apoptosis in breast cancer cells through the ZBTB16/ANXA7/Cyclin B1 axis. Acta biochimica et biophysica Sinica 3 39308302
2024 Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer. International journal of molecular sciences 1 39684934
2026 RNF168 promotes chronic colitis through ANXA7-mediated autophagy and NLRP3-driven pyroptosis. Apoptosis : an international journal on programmed cell death 0 41518435